Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 of its ELEVATE-45-201 Phase 1/2 study at an increased dose of 10 mg/kg (up from 5 mg/kg in Cohort 1). The study evaluates ENTR-601-45 for treating Duchenne muscular dystrophy in exon 45 skipping amenable patients. The company remains on track to report Cohort 1 safety and pharmacokinetic data in mid-2026.